

Financial strategy and planning; international trends & best practices




Magesh Nandagopal
Scientist, NCL Innovations
CSIR-National Chemical Laboratory, Pune


Why invest in patents?

- To protect your idea
- To increase the value of your licensing
- For visibility
- For building a portfolio
- For strategic reasons


Technology Idea –to- Market




Technology Idea –to- Market



Technology Idea –to- Market




Life cycle of pharma patent value



Source: *Nature Biotechnology*, 29, 781, (2011)

Patent Costs – Rough Trends

Germany and Japan



Example – MIT Technology Licensing Office Statistics

MIT-TLO Statistics for Fiscal Year 2012	
Total Number of Invention Disclosures	694
Number of U.S. Patents Filed	305
Number of U.S. Patents Issued	199
Number of Licenses Granted	81
Number of Options Granted	26
Number of Companies Started	16
Cash Income	\$147.5 M
Royalties	\$ 54.09 M
Patent Reimbursement	\$10.43 M
Equity Cash-In	\$ 2.75 M
Expenditure on Patents	\$16.5 M

How do the US Universities perform?

Year	Invention			License		Patent		Res Exp (\$, million) spent for each disclosure	License income as a % of Res Exp	Res Exp spent for creating one startup (\$, million)
	Disclosures			Received (in \$, millions)	Gross Appl: Newly Filed	Start-ups: Initiated	Res Exp (Total) (\$, million)			
	Options	Options	Options	Options	Options	Options	Options			
2009	20,184	4,347	951	2,313	11,961	593	53,560	2.7	4.3%	90
2008	20,020	4,125	986	3,437	12,153	595	51,205	2.6	6.7%	86
2007	19,740	4,323	751	2,703	11,749	551	48,603	2.5	5.6%	88
2006	18,792	4,176	748	2,163	11,583	551	45,062	2.4	4.8%	82
2005	17,315	4,140	749	2,128	10,236	450	42,052	2.4	5.1%	93
2004	16,817			1,472	10,486	458	40,983	2.4	3.6%	89
2003	15,463			1,418	7,899	373	38,381	2.5	3.7%	103
2002	14,358			1,304	7,316	401	34,859	2.4	3.7%	87
2001	12,612			1,112	6,367	426	29,838	2.4	3.7%	70
2000	11,933			1,275	6,049	386	27,750	2.3	4.6%	72
Total	167,234	21,111	4,185	19,325	95,799	4,784	412,294	2.5	4.7%	86

Source: Data was obtained from AUTM Licensing STATT (a licensing database run by the Association of University Technology Managers)

The top licensing earners – how they skew the picture

	Research Expenditure (\$, million)	Invention Disclosures	Startups Initiated	License Income (\$, millions)	Research Exp for each disclosure (\$, million)	License income as a % of Res Exp	Res Exp for creating a startup (\$, million)
Average per year of the top 6% universities	7,054 (17%)	3,023 (18%)	81 (17%)	1,164 (60%)	2.3	16.5 %	87
Average per year of the bottom 94% universities	34,175 (83%)	13,700 (82%)	397 (83%)	769 (40%)	2.5	2.2%	86
Average per year of all universities	41,229 (100%)	16,723 (100%)	478 (100%)	1,933 (100%)	2.5	4.7%	86

Source: Data was obtained from AUTM Licensing STATT (a licensing database run by the Association of University Technology Managers)


Licensing Income to MIT (from Momenta)

	<u>2013</u>	<u>2012</u>	<u>2011</u>
License maintenance fees	\$ 82	\$ 183	\$ 158
Royalties	<u>252</u>	<u>1,013</u>	<u>6,563</u>
Total	<u><u>\$334</u></u>	<u><u>\$1,196</u></u>	<u><u>\$6,721</u></u>

- 290,000 equity shares (in thousands)
- License maintenance fees
- Royalties
- Market Cap (Feb 26 2015): \$ 716 million

Source: Momenta Pharmaceuticals Annual Report 2013

Deferring Costs



Contacts

Dr. Magesh Nandagopal

Phone: +91-(0)20-2590 2982

Email: m.nandagopal@ncl.res.in

www.nclinnovations.org